AtaiBeckley Inc. (NASDAQ: ATAI) published results from its Phase 2a study of BPL-003, an intranasal depression treatment, in the Journal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE